Literature DB >> 2392508

Behavioral sensitization to beta-phenylethylamine (PEA): enduring modifications of specific dopaminergic neuron systems in the rat.

T Kuroki1, T Tsutsumi, M Hirano, T Matsumoto, Y Tatebayashi, K Nishiyama, H Uchimura, A Shiraishi, T Nakahara, K Nakamura.   

Abstract

Repeated daily administration of an endogenous trace amine, beta-phenylethylamine (PEA), produces behavioral sensitization such that the intensity of PEA-induced stereotyped behaviors in rats increases gradually during the treatment, and a challenge injection with PEA reinstates the enhanced stereotypy even long after withdrawal. In the present study, we examined the neurochemical changes in the central dopaminergic neurons systems in the rat for 7 drug-free days after repeated treatment with PEA (50 mg/kg, IP day for 14 or 28 days). During withdrawal, a decrease in steady-state levels of tissue dopamine (DA) and its metabolite, dihydroxyphenylacetic acid (DOPAC), was found in the mesolimbic DA nerve terminal areas of the rat brain receiving repeated PEA treatment. Fifteen minutes after challenge administration of PEA at varying doses from 6.3 to 75 mg/kg, the rats with repeated PEA treatment required smaller doses of PEA challenge than the rats with acute PEA treatment in order to obtain a significant decrease in striatal DOPAC content compared to the saline control in each treatment group. These results imply that the behavioral sensitization to PEA is accompanied by enduring modifications of the specific dopaminergic neuron systems in the rat brain. This suggestion was strongly supported by the results of the study using in vivo intracerebral dialysis, which indicated that 25 mg/kg PEA challenge elicited a remarkable increase in the extracellular DA concentrations in striatal perfusates collected from the PEA-pretreated rats, in accordance with the intensity of stereotyped behaviors. These findings argue that the hyper-responsiveness to PEA of the striatal dopaminergic neuron systems persists long after withdrawal from repeated treatment with PEA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392508     DOI: 10.1007/bf02245736

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudate nucleus by phenylethylamine.

Authors:  B A Bailey; S R Philips; A A Boulton
Journal:  Neurochem Res       Date:  1987-02       Impact factor: 3.996

2.  A new animal model for schizophrenia: interactions with adrenergic mechanisms.

Authors:  R L Borison; B I Diamond
Journal:  Biol Psychiatry       Date:  1978-04       Impact factor: 13.382

Review 3.  Amphetamine models of paranoid schizophrenia: an overview and elaboration of animal experimentation.

Authors:  L Kokkinidis; H Anisman
Journal:  Psychol Bull       Date:  1980-11       Impact factor: 17.737

4.  Behavioral sensitization is accompanied by an enhancement in amphetamine-stimulated dopamine release from striatal tissue in vitro.

Authors:  T E Robinson; J B Becker
Journal:  Eur J Pharmacol       Date:  1982-11-19       Impact factor: 4.432

5.  Monoamine oxidase in chronic schizophrenia: Studies of hormonal and other factors affecting enzyme activity.

Authors:  D L Murphy; R Belmaker; W T Carpenter; R J Wyatt
Journal:  Br J Psychiatry       Date:  1977-02       Impact factor: 9.319

6.  Ex uno multi: subtyping the schizophrenic syndrome.

Authors:  D V Jeste; J E Kleinman; S G Potkin; D J Luchins; D R Weinberger
Journal:  Biol Psychiatry       Date:  1982-02       Impact factor: 13.382

7.  Pharmacological changes induced by repeated exposure to phenylethylamine.

Authors:  G Gianutsos; S Chute
Journal:  Pharmacol Biochem Behav       Date:  1986-07       Impact factor: 3.533

8.  In vivo release of endogenous dopamine from rat caudate nucleus by phenylethylamine.

Authors:  S R Philips; A M Robson
Journal:  Neuropharmacology       Date:  1983-11       Impact factor: 5.250

9.  Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment.

Authors:  T Nishikawa; N Mataga; M Takashima; M Toru
Journal:  Eur J Pharmacol       Date:  1983-03-25       Impact factor: 4.432

10.  Phenylethylamine in paranoid chronic schizophrenia.

Authors:  S G Potkin; F Karoum; L W Chuang; H E Cannon-Spoor; I Phillips; R J Wyatt
Journal:  Science       Date:  1979-10-26       Impact factor: 47.728

View more
  6 in total

Review 1.  Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B.

Authors:  D P Holschneider; K Chen; I Seif; J C Shih
Journal:  Brain Res Bull       Date:  2001-11-15       Impact factor: 4.077

Review 2.  Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence.

Authors:  Marco Bortolato; Jean C Shih
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

3.  Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion-induced apoptosis through PI3K/Akt/GSK3β pathway in rats.

Authors:  Lin Chen; Xinbing Wei; Yunfeng Hou; Xiaoqian Liu; Senpeng Li; Baozhu Sun; Xinyong Liu; Huiqing Liu
Journal:  Neurochem Int       Date:  2014-01-22       Impact factor: 3.921

4.  Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice.

Authors:  Marco Bortolato; Sean C Godar; Shieva Davarian; Kevin Chen; Jean C Shih
Journal:  Neuropsychopharmacology       Date:  2009-08-26       Impact factor: 7.853

5.  β-Phenylethylamine requires the dopamine transporter to increase extracellular dopamine in Caenorhabditis elegans dopaminergic neurons.

Authors:  Murad Hossain; Rochelle N Wickramasekara; Lucia Carvelli
Journal:  Neurochem Int       Date:  2013-10-23       Impact factor: 3.921

Review 6.  From aggression to autism: new perspectives on the behavioral sequelae of monoamine oxidase deficiency.

Authors:  Marco Bortolato; Gabriele Floris; Jean C Shih
Journal:  J Neural Transm (Vienna)       Date:  2018-05-10       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.